JP2010524894A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524894A5
JP2010524894A5 JP2010503511A JP2010503511A JP2010524894A5 JP 2010524894 A5 JP2010524894 A5 JP 2010524894A5 JP 2010503511 A JP2010503511 A JP 2010503511A JP 2010503511 A JP2010503511 A JP 2010503511A JP 2010524894 A5 JP2010524894 A5 JP 2010524894A5
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
optionally substituted
carbocyclyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010503511A
Other languages
English (en)
Japanese (ja)
Other versions
JP5675341B2 (ja
JP2010524894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/054711 external-priority patent/WO2008128982A1/en
Publication of JP2010524894A publication Critical patent/JP2010524894A/ja
Publication of JP2010524894A5 publication Critical patent/JP2010524894A5/ja
Application granted granted Critical
Publication of JP5675341B2 publication Critical patent/JP5675341B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010503511A 2007-04-18 2008-04-18 グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体 Expired - Fee Related JP5675341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91254007P 2007-04-18 2007-04-18
US60/912,540 2007-04-18
PCT/EP2008/054711 WO2008128982A1 (en) 2007-04-18 2008-04-18 Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors

Publications (3)

Publication Number Publication Date
JP2010524894A JP2010524894A (ja) 2010-07-22
JP2010524894A5 true JP2010524894A5 (enExample) 2011-09-08
JP5675341B2 JP5675341B2 (ja) 2015-02-25

Family

ID=39684456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503511A Expired - Fee Related JP5675341B2 (ja) 2007-04-18 2008-04-18 グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体

Country Status (6)

Country Link
US (1) US9034907B2 (enExample)
EP (1) EP2160389B1 (enExample)
JP (1) JP5675341B2 (enExample)
DK (1) DK2160389T3 (enExample)
ES (1) ES2478673T3 (enExample)
WO (1) WO2008128982A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008128984A1 (en) * 2007-04-20 2008-10-30 Probiodrug Ag Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
WO2009090190A1 (en) * 2008-01-14 2009-07-23 Probiodrug Ag Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011076854A1 (en) 2009-12-22 2011-06-30 Probiodrug Ag CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
WO2011101433A1 (en) 2010-02-18 2011-08-25 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
CA2816022C (en) * 2010-10-29 2019-09-10 Emory University Quinazoline derivatives, compositions, and uses related thereto
CA2828433C (en) 2011-03-16 2020-08-04 Probiodrug Ag Diagnostic antibody assay
WO2013181135A1 (en) * 2012-05-31 2013-12-05 Emory University Quinazoline derivatives, compositions, and uses related thereto
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー pGlu−Abetaペプチドの検出のための新規の方法
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス,インコーポレーテッド ヘテロ芳香族nmda受容体モジュレーターおよびその使用
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (en) 1987-06-01 1988-12-07 American Cyanamid Company 3-heteroalkyl-2,4.quinzaoline-diones
US4684654A (en) 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
AU2002352444A1 (en) * 2001-12-20 2003-07-09 Celltech R And D Limited Quinazolinedione derivatives
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
WO2004098591A2 (en) * 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
EA016584B1 (ru) 2006-09-21 2012-06-29 Пробиодруг Аг Новые гены, родственные гену глутаминилциклазы
ES2481442T3 (es) 2006-11-09 2014-07-30 Probiodrug Ag Inhibidores novedosos de glutaminil ciclasa
US8420684B2 (en) 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
WO2008087197A1 (en) 2007-01-19 2008-07-24 Probiodrug Ag In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders
JP5612860B2 (ja) 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体

Similar Documents

Publication Publication Date Title
JP2010524894A5 (enExample)
HRP20191102T1 (hr) Sintetski međuprodukti za pripravu konjugata oligosaharid-protein
JP2013508347A5 (enExample)
HUE042847T2 (hu) A 44 xiloglukanáz család egyik variánsát tartalmazó felületaktív készítmény
EP2181399A4 (en) COMPOSITE STUFFED FLOWS
EP2213856A4 (en) AUSPUFFROHR
JP2010512298A5 (enExample)
EP2215068A4 (en) ANTIDIABETIC TRICYCLIC COMPOUNDS
DK3061467T3 (da) Sårforbinding med en bakterieadsorberende sammensætning
BRPI0922904A2 (pt) "compostos"
SE0601145L (sv) Vakuumöppningar av höghastighetstyp
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
EP2003132A4 (en) HETERO COMPOUND
JP2010504301A5 (enExample)
JP2015537008A5 (enExample)
EP2491025A4 (en) AZAAZULENVERBINDUNGEN
JP2011510079A5 (enExample)
EP2307421A4 (en) oxindole
EP2117306A4 (en) NEUROGENIC COMPOUNDS
DK1776090T3 (da) Stabiliseret prostaglandinsammensætning
JP2011037885A5 (enExample)
DE502005005800D1 (de) Selbsteinstellendes Gleitstück für Teleskopkranausleger
FI20075529A0 (fi) Nostokoukku
EP1960358A4 (en) ANTINEOPLASTIC COMPOUNDS
JP2013512203A5 (enExample)